Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes

Fewer circulating endothelial progenitor cells (EPCs) and increased plasma (C-term) stromal cell-derived factor 1 α (SDF-1α), a substrate of DPP-4, are biomarkers, and perhaps mediators, of cardiovascular risk ...

Source: Cardiovascular Diabetology - February 23, 2017 Category: Cardiology Authors: Alessandra Dei Cas, Valentina Spigoni, Monia Cito, Raffaella Aldigeri, Valentina Ridolfi, Elisabetta Marchesi, Michela Marina, Eleonora Derlindati, Rosalia Aloe, Riccardo C. Bonadonna and Ivana Zavaroni Source Type: research